Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular targets for treating cognitive dysfunction in schizophrenia.

John A Gray1, Bryan L Roth

  • 1Department of Psychiatry, University of California, San Fransico, CA, USA.

Schizophrenia Bulletin
|July 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GPCR Biased Signaling: Opportunities and Challenges.

Biochemistry·2026
Same author

Structural characterization of kappa-opioid receptor dimer in complex with two G proteins.

Nature communications·2026
Same author

Toward a Random Background for Ligand Optimization.

bioRxiv : the preprint server for biology·2026
Same author

De novo design of miniproteins targeting GPCRs.

Nature·2026
Same author

The Selectivity Implications of Docking Libraries with Greater and Lesser Similarities to Bio-like Molecules.

Journal of medicinal chemistry·2026
Same author

The polypharmacological profiles of xanomeline and N-desmethylxanomeline.

British journal of pharmacology·2026
Same journal

Reconsidering the Term "Treatment Resistant Schizophrenia".

Schizophrenia bulletin·2026
Same journal

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Schizophrenia bulletin·2026
Same journal

Comparing Apples to Oranges Obscures Tortoises Beating Hares: The Relationship Between Rate of Antipsychotic Tapering and Relapse.

Schizophrenia bulletin·2026
Same journal

Beyond the Need for Speed: D2 Receptor Affinity Predicts Relapse after Antipsychotic Tapering in First Episode Psychosis.

Schizophrenia bulletin·2026
Same journal

Correction to: The Mini-CAARMS: Development and Validation of a Short Version of the Comprehensive Assessment of AT Risk Mental States to Facilitate Preventive Psychiatry.

Schizophrenia bulletin·2026
Same journal

Longitudinal Impact of Birthweight and its Polygenic Risk Score on Glucose and Antipsychotic-Induced Weight Gain in First Episode Psychosis.

Schizophrenia bulletin·2026
See all related articles

Schizophrenia treatment inadequately addresses cognitive impairment. Novel strategies target molecular pathways like dopamine, acetylcholine, and GABA systems to improve working memory, attention, and social cognition.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Cognitive impairment is a primary feature of schizophrenia, impacting most patients.
  • These deficits often precede positive symptoms and persist despite treatment, significantly contributing to functional impairment.
  • Current antipsychotic treatments offer limited efficacy for cognitive deficits.

Purpose of the Study:

  • To review molecular targets for novel drug discovery in schizophrenia cognitive deficits.
  • Focus on improving working memory, attention, and social cognition.

Main Methods:

  • Review of current research on molecular targets for schizophrenia.
  • Exploration of neurotransmitter systems and receptor targets.

Main Results:

Related Experiment Videos

  • Identified key molecular targets including dopamine, acetylcholine (nicotinic and muscarinic), glutamate, serotonin, and GABA systems.
  • These targets are under investigation for potential therapeutic interventions.

Conclusions:

  • Developing effective treatments for schizophrenia's cognitive impairments requires targeting specific molecular pathways.
  • Further research into these targets holds promise for improving patient outcomes and daily functioning.